Navigation Links
Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
Date:11/5/2007

atment, changes in mental health as measured by the Hospital Anxiety and Depression Scale (HADS) had recovered to baseline in 67% of the patients taking Albuferon 900 mcg, compared with 57% of the peginterferon alfa-2a patients.

The treatment group taking Albuferon 1200 mcg every two weeks also recorded fewer lost days of work and less impairment of health-related quality of life on treatment than was reported for the peginterferon alfa-2a group.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commercialization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $132.5 million received to date.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus (HCV). An estimated 170 million people worldwide are infected with the virus, including nearly 4 million people in the United States. When detectable levels of HCV
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... ARBOR, Mich., May 14, 2012  Synthetic Biologics, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... Senior Vice President of Clinical & Regulatory Affairs. In ... design and implementation of all aspects of clinical development, ...
... 11, 2012 Dynatronics Corporation (NASDAQ: DYNT ) ... months ended March 31, 2012 during the morning of Tuesday, ... conference call for investors later that day at 3:30 p.m. ... month periods.  Those interested in participating should call (800) 676-3536. ...
Cached Medicine Technology:Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 2Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 3
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... teens, TOPEKA, Kan., Oct. 19 Attorney General ... with new 30-second,radio public service announcements set to air ... coincide with the busy fall season and will,air more ... November. "With teens heading off to parties, dances ...
... recent study by Celent, a leading,financial services technology research ... of eight firms leading the way as a change ... transactions. Celent,s Healthcare Banking research service based its ... Mellon,s Treasury Services division to,apply its scale, technology and ...
... SPRINGS, Colo., Oct. 19 ,Spectranetics Corporation (Nasdaq: ... 2007 third quarter financial results prior to market ... host an,investment-community conference call beginning at 9:00 a.m. ... 31 to discuss those results,and to answer questions. ...
... SANTA ANA, Calif., Oct. 19 Today, Integrated,Healthcare ... owner of,four Orange County hospitals, announced that effective ... of all of its debt instruments. The,Company said ... with Medical,Capital Corporation and affiliates of Anaheim, California, ...
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... on Thursday, November 1, 2007 at,approximately 8:00 a.m. (ET). ... (ET) hosted by Joseph C. Papa, Perrigo,s President and ... live via webcast to interested,parties on the Perrigo website ...
... AAFP President Michael Fleming, MD will serve as Digital,s Medical ... Director ... Healthcare, a Wake,Forest, NC company specializing in retinal risk assessment for ... for Primary Care. In his new role, Dr. Fleming will,provide Digital ...
Cached Medicine News:Health News:Morrison Takes Aim at Underage Drinking in New Radio Campaign 2Health News:The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing 2Health News:Spectranetics to Hold 2007 Third Quarter Financial Results Conference Call on October 31 2Health News:IHHI Announces Completion of Re-Financing 2Health News:Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director 2
... drape sheets with a low-profile, roomy ... the operative site during arthroscopic surgery. ... ports for drainage. , ,The ... a standard pack, or in custom ...
... includes bed side and near patient testing ... This growth has posed unique problems for ... and quality responsibility to decentralized areas focused ... Compounding the problem is the reality of ...
... First Consolidated Workstation to Automate Deparaffinization, ... Staining,Now you can perform deparaffinization, pretreatment, ... routine slide washing with a single ... preprogrammed Vysis protocols for fluorescence in ...
... sample preparation platform is an efficient system ... from patient samples using novel magnetic particle ... sample preparation and is cabable of processing ... a 1 ml sample volume., ,This platform ...
Medicine Products: